Research programme: neurotrophic factor 4 gene therapy - Ceregene

Drug Profile

Research programme: neurotrophic factor 4 gene therapy - Ceregene

Alternative Names: AAV-NT4; CERE-140

Latest Information Update: 28 Oct 2013

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Ceregene
  • Class Gene therapies
  • Mechanism of Action Gene transference; Nerve growth factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Retinitis pigmentosa
  • Research Glaucoma; Macular degeneration

Most Recent Events

  • 01 Oct 2013 Ceregene has been acquired by Sangamo BioSciences
  • 19 Apr 2013 Development of CERE 140 (AAV-NT4) is ongoing in USA
  • 11 Nov 2010 Ceregene receives Qualifying Therapeutic Discovery Project grant under the Patient Protection and Affordable Care Act of 2010 (PPACA)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top